Why is "Bristol Myers" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-25 01:33:30
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Bristol-Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment - Yahoo Finance
-
Should You Buy Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming Dividend? - simplywall.st
-
Is Bristol-Myers Squibb Company (BMY) a good stock to buy now? - MSN
-
Bristol Myers drug shows promise for teens with rare heart condition (BMY:NYSE) - Seeking Alpha
-
Bristol Myers Squibb’s Camzyos shows promise in adolescent trial - Investing.com
-
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) - Business Wire
-
Bristol Myers Squibb Presents Positive Results From Phase 3 Scout-Hcm Trial Demonstrating Efficacy And Safety Of Camzyos (Mavacamten) In Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy (Ohcm) - tradingview.com
-
Wedge Capital Management L L P NC Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
-
Bristol-Myers Squibb Says Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition From Oral Atypical Antipsychotics To Cobenfy - tradingview.com
-
Bristol-Myers Squibb: Dividend/Portfolio Renewal Thesis Remains Promising (NYSE:BMY) - Seeking Alpha
-
Bristol Myers Squibb Leans On AI ALS Pact As Valuation Question Persists - simplywall.st
-
Bristol-Myers Squibb (BMY) Faces Mixed Analyst Sentiment Despite Strong Momentum in Healthcare Industry - Yahoo Finance
-
Cobenfy Phase 4 Data May Reframe Bristol Myers Squibb Valuation Story - Yahoo Finance
-
Jim Cramer on Bristol-Myers Squibb: “The Stock’s Recent Pullbacks Have Represented Terrific Buying Opportunities” - Yahoo Finance
-
Bristol-Myers Squibb Company (NYSE:BMY) Looks Like A Good Stock, And It's Going Ex-Dividend Soon - Yahoo Finance
-
Why Bristol-Myers Squibb (BMY) Stock Is Up Today - Yahoo Finance
-
A Look At Bristol Myers Squibb (BMY) Valuation As Shares Show Mixed Recent Returns - Yahoo Finance
-
Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline - Yahoo Finance Singapore
-
Nepsis Inc. Acquires 90,852 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
-
Fort Washington Investment Advisors Inc. OH Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
-
Norden Group LLC Acquires 157,604 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
-
The Time Back campaign honors the most precious gift oncologists provide in cancer care: time - Bristol Myers Squibb
-
Nordea Investment Management AB Reduces Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
-
Bristol Myers Squibb Company $BMY Position Raised by Czech National Bank - MarketBeat
-
Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend? - The Motley Fool
-
Milvexian Phase 3 Wraps Up: What Bristol-Myers Squibb Investors Should Watch Next - TipRanks
-
US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma - Reuters
-
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
-
Pensionfund Sabic Purchases New Position in Bristol Myers Squibb Company $BMY - MarketBeat
-
Bristol Myers Squibb Pipeline Update With New TYK2 And CELMoD Milestones - Yahoo Finance
-
Why Bristol Myers Squibb Stock Crushed it in February - The Motley Fool
-
Is Bristol Myers' Deep Pipeline the Key to Future Growth? - Yahoo Finance
-
Can Bristol Myers Squibb’s pipeline strategy offset a major patent cliff? - Labiotech.eu
-
Bristol-Myers Squibb's new drug Camzyos succeeds in Phase III clinical trials, poised to become the first therapy for rare heart disease in adolescents. - 富途牛牛
-
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026 - Business Wire
-
Bristol Myers partners with Microsoft for AI-driven lung cancer detection - Reuters
-
Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s - statnews.com
-
Bristol-Myers Squibb: An Attractive High-Yield Stock Amid Market Uncertainty (NYSE:BMY) - Seeking Alpha
-
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now? - Yahoo Finance
-
Champions in Care - Bristol Myers Squibb
-
Is Bristol Myers Squibb (BMY) Attractively Priced After Recent Share Price Weakness - simplywall.st
-
Is It Time To Reassess Bristol Myers Squibb (BMY) After Its Recent Share Price Rebound? - Yahoo Finance
-
UBS Boosts Bristol-Myers Squibb (BMY) Price Target as Milvexian Data Looms - Yahoo Finance
-
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) - Bristol Myers Squibb
-
Building a healthier future together: Strengthening cancer care across Africa through partnership - Bristol Myers Squibb
-
Science Firsthand: Translating the promise of cell therapy - Bristol Myers Squibb
-
Bristol Myers forecasts upbeat 2026, expects Eliquis price cut to pay off - Reuters
-
Opdivo’s New cHL Approvals Reframe Bristol-Myers Squibb Growth Story - Yahoo Finance
-
How Bristol Myers Squibb Transformed Working Capital to Fund Its Future - Harvard Business Review
-
Bristol Myers Squibb Adds Reblozyl Data And AI To Pipeline Story - Yahoo Finance
-
Bristol Myers claims success in study of another next-gen blood cancer drug - biopharmadive.com
-
C2C4C 2025 raises over $2M to advance cancer research - Bristol Myers Squibb
-
Bristol Myers Squibb honoured with the prestigious Prix Galien Award - Bristol Myers Squibb
-
Artificial Intelligence at Bristol Myers Squibb – Two Use Cases - Emerj Artificial Intelligence Research
-
A Look At Bristol Myers Squibb (BMY) Valuation As Recent Results Shape Growth And Cost Outlook - simplywall.st
-
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer - biopharmadive.com
-
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
-
Cash leadership office for Bristol Myers Squibb - EY
-
Buy Bristol Myers Squibb Stock. The Drugmaker Is Too Cheap to Ignore. - Barron's
-
Bristol-Myers Squibb's revenue by region 2023-2025 - Statista
-
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters
-
Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend? - AOL.com
-
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab) - Business Wire
-
How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story - Yahoo Finance
-
Human connections driving innovation & impact at GPS - Bristol Myers Squibb
-
Bristol-Myers Squibb employment 2025 - Statista
-
insitro expands Bristol Myers Squibb ALS collaboration - Investing.com
-
Bristol-Myers Squibb Expands Cancer Efforts With New AI And Drug Deals - Yahoo Finance
-
Nurse practitioners impact patient care and foster collaboration - Bristol Myers Squibb
-
Assessing Bristol Myers Squibb (BMY) Valuation After Earnings Beat And Pipeline Optimism - Yahoo Finance
-
Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial - statnews.com
-
Bristol Myers Squibb Announces Dividend - Business Wire
-
Evinova, Bristol Myers Squibb Partner to Apply AI to Global Clinical Development - Applied Clinical Trials Online
-
Is Bristol Myers Squibb (BMY) Pricing Look Attractive After Recent Share Price Climb - Yahoo Finance
-
Redefining biologics & cell therapy manufacturing at Devens - Bristol Myers Squibb
-
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference - Business Wire
-
Bristol-Myers Squibb's revenue from 2006 to 2025 - Statista
-
Bristol Myers Squibb signs to Life Science Cares National Campaign to advance health equity and fight food insecurity - ROI-NJ
-
Bristol Myers plans UK launch of schizophrenia drug Cobenfy, matching US price - Reuters
-
Bristol Myers Squibb Moves Into In Vivo CAR T with $1.5 Billion Orbital Buy - Inside Precision Medicine
-
Bristol Myers to sell 60% stake in China joint venture - Reuters
-
Here’s What Analysts Are Saying About Bristol-Myers Squibb Company (BMY) - Yahoo Finance
-
Is Bristol Myers Squibb (BMY) Still Undervalued After Its Recent Share Price Rebound? - Yahoo Finance
-
Patient Advocate Foundation Announces $1 Million Donation from Bristol Myers Squibb Foundation - Patient Advocate Foundation
-
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - europeanpharmaceuticalreview.com
-
Bristol-Myers Squibb stock price forecast: short-term resistance holds as BMY slips 1.5% - Traders Union
-
Goldman Sachs Raises Bristol-Myers (BMY) Target, Keeps Neutral Rating - Yahoo Finance
-
How Bristol Myers Squibb gave Time Back to oncologists at ASH 2025 - Medical Marketing and Media
-
Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable” - Yahoo Finance
-
What Bristol-Myers Squibb (BMY)'s Triple-Negative Breast Cancer Phase III Survival Win Means For Shareholders - Yahoo Finance
-
Bristol Myers Squibb discloses 247 more layoffs in NJ (updated) - NJBIZ
-
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26) - Business Wire
-
Bristol-Myers Squibb Resets Pipeline With RNA Deals And Cost Focus - Yahoo Finance
-
Bristol Myers Squibb CEO Chris Boerner says company culture was the missing piece of his ‘patent cliff’ plan - Fortune
-
Why Is Bristol-Myers Squibb (BMY) Stock Rocketing Higher Today - Yahoo Finance
-
Texas sues Bristol Myers, Sanofi for concealing blood thinner Plavix's alleged ineffectiveness - Reuters
-
What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)? - Yahoo Finance
-
Bristol Myers, Takeda to pool data for AI-based drug discovery - Reuters
-
JPM26: Bristol Myers CEO to 'cast a broad net' as business development remains a top priority - Fierce Pharma
-
Jim Cramer Discusses Bristol Myers’s (BMY) Cobenfy Drug - Yahoo Finance
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.